Rhythm Pharmaceuticals (RYTM) Interest Expenses (2022 - 2026)

Rhythm Pharmaceuticals (RYTM) has 5 years of Interest Expenses data on file, last reported at $4.6 million in Q1 2026.

• Interest Expenses for Q1 2026 came in at $4.6 million, down 15.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.8 million (down 4.56% YoY), and the FY2025 annual result was $20.6 million, changed 0.1% from the prior year.
• Interest Expenses slipped to $4.6 million in Q1 2026 per RYTM's latest filing, from $4.6 million in the prior quarter.
• Over five years, Interest Expenses peaked at $5.8 million in Q2 2025 and troughed at $46000.0 in Q2 2022.
• A 5-year average of $4.0 million and a median of $4.6 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses jumped 7080.43% in 2023, then fell 15.27% in 2025.
• A 5-year view of Interest Expenses shows it stood at $3.0 million in 2022, then surged by 51.11% to $4.6 million in 2023, then advanced by 19.71% to $5.4 million in 2024, then declined by 15.27% to $4.6 million in 2025, then dropped by 0.69% to $4.6 million in 2026.
• Business Quant data shows RYTM's Interest Expenses at $4.6 million in Q1 2026, $4.6 million in Q4 2025, and $4.7 million in Q3 2025.